Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics (NASDAQ: TVTX) has announced the granting of inducement equity awards to five new employees on March 10, 2025. The compensation package includes:
- 36,000 shares in stock options with an exercise price of $17.87 per share
- 41,200 restricted stock units (RSUs)
The stock options are non-qualified, have a 10-year term, and vest over four years with 25% vesting after one year and the remaining 75% vesting monthly over 36 months. The RSUs vest over four years, with 25% vesting annually. These grants were made outside the company's 2018 Equity Incentive Plan but are subject to its terms, awarded as employment inducements under Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) ha annunciato il conferimento di premi azionari per incentivare cinque nuovi dipendenti il 10 marzo 2025. Il pacchetto di compensi include:
- 36.000 azioni in opzioni azionarie con un prezzo di esercizio di $17.87 per azione
- 41.200 unità azionarie vincolate (RSU)
Le opzioni azionarie sono non qualificate, hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente per 36 mesi. Le RSU maturano in quattro anni, con il 25% che matura annualmente. Questi conferimenti sono stati effettuati al di fuori del Piano di Incentivazione Azionaria 2018 dell'azienda, ma sono soggetti ai suoi termini, concessi come incentivi all'occupazione secondo la Regola di Quotazione Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) ha anunciado la concesión de premios de acciones para incentivar a cinco nuevos empleados el 10 de marzo de 2025. El paquete de compensación incluye:
- 36,000 acciones en opciones sobre acciones con un precio de ejercicio de $17.87 por acción
- 41,200 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones son no calificadas, tienen un plazo de 10 años y se consolidan durante cuatro años, con el 25% consolidándose después de un año y el 75% restante consolidándose mensualmente durante 36 meses. Las RSUs se consolidan durante cuatro años, con el 25% consolidándose anualmente. Estas concesiones se realizaron fuera del Plan de Incentivos de Acciones 2018 de la empresa, pero están sujetas a sus términos, otorgadas como incentivos laborales bajo la Regla de Cotización de Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX)는 2025년 3월 10일에 다섯 명의 신규 직원에게 유인 주식 보상을 부여했다고 발표했습니다. 보상 패키지는 다음과 같습니다:
- 주당 $17.87의 행사가격으로 36,000주 주식 옵션
- 41,200 제한 주식 단위(RSU)
주식 옵션은 비자격 옵션이며, 10년의 기간을 가지며, 4년에 걸쳐 25%가 1년 후에 발생하고 나머지 75%는 36개월 동안 매달 발생합니다. RSU는 4년에 걸쳐 발생하며, 25%가 매년 발생합니다. 이러한 보상은 회사의 2018년 주식 인센티브 계획 외부에서 이루어졌지만, 해당 계획의 조건에 따라 부여되며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인으로 제공됩니다.
Travere Therapeutics (NASDAQ: TVTX) a annoncé le 10 mars 2025 l'octroi de récompenses en actions incitatives à cinq nouveaux employés. Le package de rémunération comprend :
- 36 000 actions sous forme d'options d'achat d'actions avec un prix d'exercice de $17.87 par action
- 41 200 unités d'actions restreintes (RSUs)
Les options d'achat d'actions ne sont pas qualifiées, ont une durée de 10 ans et s'acquièrent sur quatre ans, avec 25 % s'acquérant après un an et les 75 % restants s'acquérant mensuellement sur 36 mois. Les RSUs s'acquièrent sur quatre ans, avec 25 % s'acquérant annuellement. Ces attributions ont été effectuées en dehors du Plan d'Incitation à l'Équité 2018 de l'entreprise, mais sont soumises à ses conditions, accordées comme incitations à l'emploi en vertu de la Règle de Cotation Nasdaq 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) hat am 10. März 2025 die Gewährung von Anreizaktien an fünf neue Mitarbeiter bekannt gegeben. Das Vergütungspaket umfasst:
- 36.000 Aktien in Form von Aktienoptionen mit einem Ausübungspreis von $17.87 pro Aktie
- 41.200 Restricted Stock Units (RSUs)
Die Aktienoptionen sind nicht qualifiziert, haben eine Laufzeit von 10 Jahren und vesten über einen Zeitraum von vier Jahren, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über 36 Monate vesten. Die RSUs vesten über vier Jahre, wobei 25% jährlich vesten. Diese Gewährungen wurden außerhalb des Aktienanreizplans 2018 des Unternehmens vorgenommen, unterliegen jedoch dessen Bedingungen und wurden als Beschäftigungsanreize gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- Company demonstrates ability to attract new talent with competitive equity compensation packages
- Stock options granted at current market price ($17.87) showing confidence in fair valuation
- Potential dilution of existing shareholders from additional 77,200 shares
- Increased stock-based compensation expense over the next 4 years
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
The RSUs vest over four years, with
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact Info
| Media: 888-969-7879 mediarelations@travere.com | Investors: 888-969-7879 IR@travere.com |
FAQ
What is the vesting schedule for TVTX's new employee stock options granted in March 2025?
How many shares were included in Travere Therapeutics' March 2025 inducement grants?
What is the exercise price for TVTX's March 2025 inducement stock options?
How do the RSUs vest in Travere's March 2025 inducement grants?
